KB-1241

RG7716-ANG2-hIgG1

×
Please enable JavaScript in your browser to complete this form.
12243
Home » Antibodies » RG7716-ANG2-hIgG1

Background of RG7716-ANG2-hIgG1

RG7716 (also known as Faricimab) was an investigational drug developed by Genentech, a subsidiary of Roche. RG7716 is a novel bispecific antibody designed to target two key proteins involved in various eye diseases, particularly retinal diseases like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). RG7716-ANG2-hIgG1 is is a monoclonal antibody specifically designed to target ANG2 in order to provide targeted therapy.

Specifications

Catalog NumberKB-1241
Antibody NameRG7716-ANG2-hIgG1
IsotypeHuman IgG1,lambda
TargetANG2
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Anti-VEGF/anti-angiopoietin-2 bispecific antibody RG7716 in diabetic macular edema: complete 36-week results from the phase 2, multicenter, randomized, active treatment-controlled BOULEVARD clinical trial
Please enable JavaScript in your browser to complete this form.